Covestor LTD Genmab A/S Transaction History

Covestor LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$35.27 - $42.24 $1,904 - $2,280	-54 Reduced 5.95%	853 $30,000
Q2 2023 Aug 11, 2023	SELL	$37.4 - $42.94 $897 - $1,030	-24 Reduced 2.58%	907 $34,000
Q1 2023 May 15, 2023	BUY	$34.88 - $43.22 $1,499 - $1,858	43 Added 4.84%	931 $35,000
Q4 2022 Feb 13, 2023	SELL	$33.8 - $47.06 $878 - $1,223	-26 Reduced 2.84%	888 $37,000
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $504 - $5,977	16 Added 1.78%	914 $29,000
Q2 2022 Aug 10, 2022	SELL	$26.83 - $38.57 $1,046 - $1,504	-39 Reduced 4.16%	898 $29,000
Q1 2022 May 13, 2022	SELL	$30.95 - $39.68 $247 - $317	-8 Reduced 0.85%	937 $34,000
Q4 2021 Feb 10, 2022	BUY	$35.87 - $47.12 $33,897 - $44,528	945 New	945 $37,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

Stay updated on Covestor LTD with notifications on news.